Is Cannabis Legal in France?

Medical Cannabis in France

France's relationship with medical cannabis has been cautious and incremental. For decades the country maintained an absolute prohibition, even as neighbouring Germany and the Netherlands built functioning medical frameworks. That began to change in October 2019, when the National Agency for Medicines and Health Products Safety (ANSM) convened a scientific committee to evaluate the clinical case for CBMPs.

The result was a two-year experimentation programme that launched in March 2021, enrolling patients through a network of specialist centres and general practitioners. The programme targeted five therapeutic areas: treatment-resistant neuropathic pain, chemotherapy-induced nausea and vomiting, palliative care, spasticity associated with multiple sclerosis, and drug-resistant epilepsy. Products were supplied initially through imports, predominantly from the Netherlands and later Germany, pending the development of a domestic supply chain.

After three years of clinical data collection, a government decree issued in March 2024 formally transitioned the programme from experimental to permanent status. This was a significant regulatory milestone: France joined the growing list of EU member states with an established, legally permanent CBMP framework.

Patient Numbers and Access

Estimates from ANSM and independent analysts suggest approximately 70,000 patients were accessing CBMPs through the permanent programme by the close of 2024. Access remains conditional on specialist referral for most indications, and reimbursement by the national health insurer (Assurance Maladie) is not yet universal across all CBMP formulations. This creates a practical access barrier for lower-income patients, an issue the regulator has acknowledged but not yet resolved through the 2026 timetable.

Products available within the framework include dried flower for vaporisation, oil-based preparations, and standardised extracts. The ANSM controls import licences, quality standards, and the list of authorised formulations. Domestic cultivation for medicinal purposes remains under discussion; no licences had been granted for pharmaceutical-grade French production as of early 2026.

Possession and Adult-Use Rules

France has never decriminalised cannabis possession in a meaningful sense. The Law of 31 December 1970 classifies cannabis as a stupefiant, placing it under the same legal category as heroin and cocaine. Any possession — however small the quantity — technically constitutes a criminal offence under French law, carrying a penalty of up to one year in prison and a €3,750 fine.

In practice, a 2019 legislative reform introduced the forfaitisation system: a simplified fixed-penalty fine of €200, payable on the spot, for first-time minor possession offences. The intention was to reduce the burden on the court system and accelerate processing of low-level cannabis incidents. Police can issue this administrative fine without referring the matter to the prosecutor's office.

However, the €200 fine is a discretionary tool, not a decriminalisation. Prosecutors retain the right to pursue criminal charges regardless of whether a fine has been issued. Repeat offenders, individuals carrying quantities above what police regard as personal-use amounts, or those caught in circumstances suggesting supply face full criminal proceedings. The distinction between personal use and supply is not defined in law by quantity thresholds — it is left to prosecutorial judgement, which critics argue creates arbitrary enforcement.

France reports some of the highest rates of cannabis consumption in Europe despite its strict legal framework, a paradox that reform advocates frequently cite. According to OFDT (Observatoire français des drogues et des tendances addictives), approximately 900,000 people use cannabis daily in France — the highest daily use rate in the EU.

Business and Licensing Landscape

France offers a narrow but growing set of legitimate commercial opportunities in the cannabis sector. The most clearly defined route is the CBMP supply chain: companies authorised by the ANSM to import or distribute licensed medicinal products for the permanent medical programme. This is a tightly regulated market with high entry barriers, but it represents a stable and expanding revenue opportunity as patient numbers scale.

Hemp cultivation has a longer history in France. The country is one of Europe's largest hemp producers, particularly for fibre and seed. French law permits the cultivation of EU-approved hemp varieties with a THC content not exceeding 0.3% in the plant at harvest. Businesses operating in the CBD sector must navigate an evolving regulatory landscape shaped both by French administrative law and European Court of Justice precedent on the free movement of CBD products between member states.

There is no legal route to cultivation, processing, or sale of adult-use cannabis in France. Companies considering market entry for the medical segment should engage with the ANSM's guidance on import authorisations and the specific dossier requirements for CBMP distribution. Pharmaceutical-grade manufacturing on French soil is not yet authorised, though the regulatory framework is expected to evolve as the permanent programme matures.

Penalties for Cannabis Offences

The French penal framework distinguishes between possession, personal use, and trafficking, though the lines between them are determined by prosecutorial discretion rather than fixed statutory thresholds.

• Simple possession / use: Up to one year in prison and a €3,750 fine. In practice, first-time minor possession is typically handled with a €200 fixed fine under the 2019 system.
• Supply and trafficking: Up to 10 years in prison and a €7.5 million fine for individuals. Aggravated trafficking in an organised gang carries up to 30 years imprisonment.
• Importing or exporting: Up to 10 years and €7.5 million; aggravated penalties apply for large-scale operations.
• Cultivation (illicit): Treated as equivalent to trafficking in terms of penalties.

French courts have been broadly consistent in their application of trafficking penalties, which are among the most severe in the EU. The social costs of the current enforcement approach — estimated at several billion euros annually in policing and judicial resources — have fuelled academic and civil society debate about the cost-effectiveness of prohibition.

2026 Outlook

The near-term trajectory for France is consolidation and expansion of the medical programme rather than structural reform of the prohibition framework. The March 2024 decree establishing the permanent CBMP system creates a regulatory foundation on which patient numbers, product diversity, and supply chain depth can grow through 2026 and beyond.

Key developments to watch in 2026 include: the possible extension of reimbursement eligibility under Assurance Maladie; the ANSM's ongoing review of additional therapeutic indications; and progress on the question of domestic French cultivation for pharmaceutical supply. The latter would represent a commercially significant shift, creating a market for licensed cultivators and processors that does not currently exist.

On adult use, France's political landscape offers little near-term prospect of reform. The country's two major parliamentary blocs — the centre coalition and the Rassemblement National — are both opposed to legalisation. Smaller progressive parties and some regional administrations continue to push for debate, but without executive support, legislative change is not anticipated before at least 2028 under current political conditions.

France's CBD market will continue to evolve in line with EU-level regulatory clarity. The European Commission's classification of CBD products and any harmonised THC thresholds across member states will have a direct bearing on the scale and structure of the French CBD sector.